aTyr Pharma Inc (LIFE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Sanjay S. Shukla
Employees:
50
3545 JOHN HOPKINS COURT, STE #250, SAN DIEGO, CA 92121
858-731-8389

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trials for treatment of other interstitial lung diseases (ILDs) The company was incorporated in 2005 and is headquartered in San Diego, California.

Data derived from most recent annual or quarterly report
Market Cap 53.815 Million Shares Outstanding28.625 Million Avg 30-day Volume 249.31 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.46
Price to Revenue0.0 Debt to Equity0.0 EBITDA-32.345 Million
Price to Book Value1.3041 Operating Margin0.0 Enterprise Value34.448 Million
Current Ratio18.887 EPS Growth0 Quick Ratio18.019
1 Yr BETA 0.8354 52-week High/Low 6.4 / 1.82 Profit Margin0.0
Operating Cash Flow Growth-116.1623 Altman Z-Score8.974 Free Cash Flow to Firm -25.231 Million
Earnings Report2023-05-09

Are you looking for these stocks instead?

View SEC Filings from LIFE instead.

View recent insider trading info

aTyr Pharma Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding LIFE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LIFE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-21 by SHUKLA SANJAY
  • 4: filed on 2023-02-21 by BROADFOOT JILL MARIE
  • 4: filed on 2023-02-21 by DENYES NANCY
  • 4: filed on 2023-02-06 by DENYES NANCY
  • 4: filed on 2023-02-06 by BROADFOOT JILL MARIE
  • 4: filed on 2023-02-06 by SHUKLA SANJAY
  • 4: filed on 2022-07-06 by SHUKLA SANJAY
  • 4: filed on 2022-05-26 by DENYES NANCY
  • 4: filed on 2022-05-26 by BROADFOOT JILL MARIE
  • 4: filed on 2022-05-26 by SHUKLA SANJAY

    • Events (8k)

  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-06:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-17:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    1.6 Thousand total shares from 1 transactions

    Exercise Derivative Conversion (M)

    16.8 Thousand total shares from 3 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BROADFOOT JILL MARIE CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-02-16 3

    DENYES NANCY GENERAL COUNSEL

    • Officer
    		 0 2023-02-16 3

    SHUKLA SANJAY PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-02-16 5

    CLARKE JOHN K

    • Director
    		 6,000 2022-04-26 1

    SCHIMMEL PAUL

    • Director
    		 6,000 2022-04-26 1

    COUGHLIN TIMOTHY

    • Director
    		 6,000 2022-04-26 1

    ZAKNOEN SARA

    • Director
    		 6,000 2022-04-26 1

    GROSS JANE A

    • Director
    		 6,000 2022-04-26 1

    LUCAS SVETLANA

    • Director
    		 6,000 2022-04-26 1

    HATFIELD JEFFREY S.

    • Director
    		 0 2020-05-06 0

    BLAIR JAMES C

    • Director
    		 0 2019-05-08 0

    MENDLEIN JOHN

    • Director
    		 0 2019-05-08 0

    AMANULLAH ASHRAF SEE REMARKS

    • Officer
    		 No longer subject to file 2018-05-31 0

    NASHAT AMIR

    • Director
    		 0 2018-05-15 0

    ECOR1 CAPITAL FUND QUALIFIED, L.P.

    • 10% Owner
    		 No longer subject to file 2018-05-14 0

    BLACKBURN STAN

    • SEE REMARKS
    		 11,954 2018-03-20 0

    BLAKE JOHN T SENIOR VICE PRESIDENT, FINANCE

    • Officer
    		 1,932 2018-02-06 0

    KING DAVID JOHN CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2018-02-06 0

    AKKARAJU SRINIVAS

    • Director
    		 0 2017-05-09 0

    GOLDBERG MARK ALAN

    • Director
    		 0 2017-05-09 0

    RAVINDRAN SANUJ K. CHIEF BUSINESS OFFICER

    • Officer
    		 0 2017-02-07 0

    MATSUOKA GROVE SEE REMARKS

    • Officer
    		 0 2017-02-07 0

    CUBITT ANDREW VP, PRODUCT PROTECTION

    • Officer
    		 0 2016-09-13 0

    FALBERG KATHRYN E

    • Director
    		 0 2016-05-24 0

    BLACKBURN KELLY VP, CLINICAL AFFAIRS

    • Officer
    		 0 2016-03-28 0

    CHRZANOWSKI HOLLY D. SEE REMARKS

    • Officer
    		 0 2016-01-27 0

    MCKEW JOHN C. VP, RESEARCH

    • Officer
    		 0 2016-01-27 0

    ASHLOCK MELISSA A. SEE REMARKS

    • Officer
    		 0 2016-01-27 0

    GRAHAM MARCY SEE REMARKS

    • Officer
    		 0 2016-01-04 0

    RAMSDELL FRED VP, IMMUNOLOGY

    • Officer
    		 0 2015-10-01 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 No longer subject to file 2015-05-12 0

    DP VIII ASSOCIATES, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    • Director
    • 10% Owner
    		 13,414 2015-05-12 0

    DOMAIN PARTNERS VIII, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    • Director
    • 10% Owner
    		 1,807,820 2015-05-12 0

    CHP II LP

    CHP II MANAGEMENT, LLC

    HULL BRANDON H

    PARK JOHN JOSEPH

    • 10% Owner
    		 No longer subject to file 2015-05-12 0

    ALTA PARTNERS VIII, L.P.

    ALTA PARTNERS MANAGEMENT VIII, LLC

    JANNEY DANIEL

    CHAMPSI FARAH

    NOHRA GUY P

    • 10% Owner
    		 No longer subject to file 2015-05-12 0

    SOFINNOVA VENTURE PARTNERS IX, L.P.

    SOFINNOVA MANAGEMENT IX, L.L.C.

    HEALY JAMES

    POWELL MICHAEL

    MEHRA ANAND

    • 10% Owner
    		 No longer subject to file 2015-05-12 0

    POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

    POLARIS VENTURE PARTNERS V, L.P.

    POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

    POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

    POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

    • 10% Owner
    		 No longer subject to file 2015-05-12 0

    DOMAIN ASSOCIATES

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    KAMDAR KIM P.

    • Director
    • 10% Owner
    		 12,572 2015-05-06 0

    SOFINNOVA VENTURE PARTNERS IX, L.P.

    SOFINNOVA MANAGEMENT IX, L.L.C.

    HEALY JAMES

    POWELL MICHAEL

    AKKARAJU SRINIVAS

    MEHRA ANAND

    • 10% Owner
    		 0 2015-05-06 0

    CHEREAU FREDERIC COO & PRESIDENT

    • Officer
    		 12,867 2015-05-06 0

    WEINER DAVID M. CHIEF MEDICAL OFFICER

    • Officer
    		 5,028 2015-05-06 0

    DITTAMORE RAYMOND V

    • Director
    		 27,073 2014-01-06 0

    STEVENSON MARK PRESIDENT & COO

    • Officer
    		 208,866 2013-12-18 0

    LUCIER GREGORY T CHIEF EXECUTIVE OFFICER

    • Officer
    		 888,382 2012-12-26 0

    LORIMIER BRADLEY G

    • Director
    		 8,200 2012-12-11 0

    LEVINE ARNOLD J

    • Director
    		 1,081 2012-10-15 0

    ANDREWS RONALD ASBURY PRESIDENT, MEDICAL SCIENCES

    • Officer
    		 3,330 2012-04-27 0

    LEDDY PETER MICHAEL SVP, GLOBAL HUMAN RESOURCES

    • Officer
    		 27,525 2011-11-22 0

    PESCOVITZ ORA H.

    • Director
    		 1,133 2011-08-22 0

    MATRICARIA RONALD A

    • Director
    		 70,000 2011-08-01 0

    BRUST BERND PRESIDENT, MOLECULAR MEDICINE

    • Officer
    		 23,704 2011-01-03 0

    MILLER JOHN L PRESIDENT, GENETIC SYSTEMS

    • Officer
    		 98,339 2010-12-17 0

    BARTHELEMY NICOLAS PRES, COMMERCIAL OPERATIONS

    • Officer
    		 72,329 2010-12-10 0

    COTTINGHAM JOHN A SVP, CHIEF LEGAL OFFICER

    • Officer
    		 53,444 2009-12-15 0

    LONGFIELD WILLIAM H

    • Director
    		 13,000 2009-05-11 0

    ADAM GEORGE F JR

    • Director
    		 2,747 2009-05-08 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SHUKLA SANJAY - Director - Officer PRESIDENT AND CEO

    		2023-02-21 17:08:11 -0500 2023-02-16 A 336,096 a 336,096 direct

    DENYES NANCY - Officer GENERAL COUNSEL

    		2023-02-21 17:00:23 -0500 2023-02-16 A 84,023 a 84,023 direct

    BROADFOOT JILL MARIE - Officer CHIEF FINANCIAL OFFICER

    		2023-02-21 17:04:44 -0500 2023-02-16 A 84,023 a 84,023 direct

    BROADFOOT JILL MARIE - Officer CHIEF FINANCIAL OFFICER

    		2023-02-06 19:00:37 -0500 2023-02-06 S 1,566 $2.36 d 15,460 direct -3.6437 -10.9312 -23.4818 0.0 1 -23.8866 28

    SHUKLA SANJAY - Director - Officer PRESIDENT AND CEO

    		2023-02-06 18:57:54 -0500 2023-02-03 M 10,375 a 61,173 direct -3.6437 -10.9312 -23.4818 0.0 1 -23.8866 28

    SHUKLA SANJAY - Director - Officer PRESIDENT AND CEO

    		2023-02-06 18:57:54 -0500 2023-02-03 M 10,375 d 31,125 direct

    BROADFOOT JILL MARIE - Officer CHIEF FINANCIAL OFFICER

    		2023-02-06 19:00:37 -0500 2023-02-03 M 3,750 a 17,026 direct -3.6437 -10.9312 -23.4818 0.0 1 -23.8866 28

    BROADFOOT JILL MARIE - Officer CHIEF FINANCIAL OFFICER

    		2023-02-06 19:00:37 -0500 2023-02-03 M 3,750 d 11,250 direct

    DENYES NANCY - Officer GENERAL COUNSEL

    		2023-02-06 19:03:30 -0500 2023-02-03 M 2,688 a 7,079 direct -3.6437 -10.9312 -23.4818 0.0 1 -23.8866 28

    DENYES NANCY - Officer GENERAL COUNSEL

    		2023-02-06 19:03:30 -0500 2023-02-03 M 2,688 d 8,062 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ATYR PHARMA INC LIFE 2023-03-24 22:15:03 UTC 3.8322 0.9878 350000
    ATYR PHARMA INC LIFE 2023-03-24 21:45:03 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 21:15:03 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 20:45:03 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 20:15:04 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 19:45:03 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 19:15:04 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 18:45:04 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 18:15:03 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 17:45:03 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 17:15:03 UTC 3.8345 0.9855 350000
    ATYR PHARMA INC LIFE 2023-03-24 16:45:03 UTC 3.8322 0.9878 350000
    ATYR PHARMA INC LIFE 2023-03-24 16:15:03 UTC 3.8322 0.9878 300000
    ATYR PHARMA INC LIFE 2023-03-24 15:45:03 UTC 3.8322 0.9878 300000
    ATYR PHARMA INC LIFE 2023-03-24 15:15:03 UTC 3.8322 0.9878 350000
    ATYR PHARMA INC LIFE 2023-03-24 14:45:03 UTC 3.8322 0.9878 350000
    ATYR PHARMA INC LIFE 2023-03-24 14:15:03 UTC 3.8322 0.9878 300000
    ATYR PHARMA INC LIFE 2023-03-24 13:45:03 UTC 3.5292 1.0408 500000
    ATYR PHARMA INC LIFE 2023-03-24 13:15:04 UTC 3.5292 1.0408 500000
    ATYR PHARMA INC LIFE 2023-03-24 12:45:03 UTC 3.5292 1.0408 500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments